Press Releases

MedGenome exhibits its sequencing and informatics solutions at the AACR Annual Meeting. Attendees can see the company’s oncology-focused genomics offerings firsthand.

MedGenome-linked research identifies candidate targets for a gallbladder cancer vaccine. The findings add to a pipeline of tumor-specific immunotherapy targets.

MedGenome secures a USD 55 million investment led by LeapFrog Investments. The funding backs continued growth in South Asian genetic diagnostics, research, and data services.

MedGenome adopts the Applied Biosystems Axiom genotyping platform to support large-scale genetic studies. The platform is tailored to capture genetic variation across South Asian populations.

A MedGenome-associated study pinpoints a targetable mutation in lung cancer. The finding points to a potential avenue for more precise treatment strategies.

MedGenome research proposes a personalized cancer vaccine strategy for patients with Lynch Syndrome. The approach targets tumor-specific antigens linked to the condition.

MedGenome presents its personalized cancer vaccine approach for Lynch Syndrome patients. The talk details the science behind targeting tumor-specific antigens.

MedGenome expands its next-generation sequencing capabilities to include single-cell sequencing. The move broadens the company’s service menu for high-resolution cellular analysis.

MedGenome closes a $30 million Series C round led by Sequoia India and Sofina. The funding supports continued growth of the company’s genomics platform.

MedGenome shares research on how CD8 T-cell infiltration relates to patient survival outcomes. The work adds to a growing body of immune-profiling research in cancer.